106 related articles for article (PubMed ID: 1313740)
21. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
22. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
24. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
25. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
[TBL] [Abstract][Full Text] [Related]
26. Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice.
Lee CK; Son SH; Park KK; Park JH; Lim SS; Kim SH; Chung WY
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):48-54. PubMed ID: 18484961
[TBL] [Abstract][Full Text] [Related]
27. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
28. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
29. Radioprotectors as late preventive agents against carbon tetrachloride induced liver necrosis: protection by 2-(3-aminopropylamino) ethylphosphorothioic acid (WR2721).
Valles EG; de Castro CR; Castro JA
Exp Mol Pathol; 1995 Oct; 63(2):101-9. PubMed ID: 8941044
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of antineoplastic effects of cisplatin by a calmodulin antagonist (W-7) in nude mice bearing human ovarian carcinoma.
Oomori K; Kikuchi Y; Kita T; Iwano I; Kizawa I; Kato K
Cancer Detect Prev; 1988; 12(1-6):481-6. PubMed ID: 3180142
[TBL] [Abstract][Full Text] [Related]
31. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis.
Epperly MW; Carpenter M; Agarwal A; Mitra P; Nie S; Greenberger JS
In Vivo; 2004; 18(4):401-10. PubMed ID: 15369176
[TBL] [Abstract][Full Text] [Related]
32. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
33. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
Sirotnak FM; Schmid FA; DeGraw JI
Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
[TBL] [Abstract][Full Text] [Related]
34. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
[TBL] [Abstract][Full Text] [Related]
35. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid against induction of altered hepatocyte foci in rats treated once with gamma-radiation within one day after birth.
Grdina DJ; Peraino C; Carnes BA; Hill CK
Cancer Res; 1985 Nov; 45(11 Pt 1):5379-81. PubMed ID: 2865003
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
39. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
40. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
Millar JL; McElwain TJ; Clutterbuck RD; Wist EA
Am J Clin Oncol; 1982 Jun; 5(3):321-8. PubMed ID: 6282111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
